Skip to main content
Fig. 5 | Molecular Cancer

Fig. 5

From: Genetic fusion of CCL11 to antigens enhances antigenicity in nucleic acid vaccines and eradicates tumor mass through optimizing T-cell response

Fig. 5

Dynamic analysis of phenotypic differentiation of specific CD8 + T cell in blood, spleen and lymph nodes. A and B The frequencies of SLEC and MPEC subpopulations of CD8 + tetramer + T cells (mean ± SEM) in blood (A) and spleen (B) at 14 days after E6E7 or CCL11-E6E7 immunization (n = 7 mice for each group). P-value reflects statistical differences in specified subgroups. C Graphs (mean ± SEM) show the percentage of CD62L + T cells of MPEC cells in spleen on day 14. D Graphs (mean ± SEM) show the number of CD62L + MPEC cells in spleen on day 14. E and F Graphs (mean ± SEM) show the number of TCF1 + PD-1- CD62L + cells of tetramer + cells in the spleen (E) or lymph node (F) on day 14. G and H The frequencies of SLEC and MPEC subpopulations of CD8 + tetramer + T cells (mean ± SEM) in blood (G) and spleen (H) at 21 days after E6E7 or CCL11-E6E7 immunization (n = 7 mice for each group). P-value reflects statistical differences in specified subgroups. I Graphs (mean ± SEM) show the percentage of CD62L + T cells of MPEC cells in spleen on day 21. J Graphs (mean ± SEM) show the number of CD62L + MPEC cells in spleen on day 21. K and L Graphs (mean ± SEM) show the number of TCF1 + PD-1- CD62L + cells of tetramer + cells in the spleen (E) or lymph node (F) on day 21. Statistical significance was calculated using a student's t-test, where "ns" stands for not significant

Back to article page

Molecular Cancer

ISSN: 1476-4598